Iverson Genetics

metamarkgenetics.com

Iverson Genetics Diagnostics is helping lead the way in genetic testing to health care providers to promote early disease detection and to help physicians achieve optimal dosing of critical medications. Iverson's genetic tests will become the model for comprehensive disease detection and informed treatment, ushering in a new era of predictive, preventative and affordable health care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

news image

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More

INDUSTRIAL IMPACT

SENDA BIOSCIENCES BOLSTERS EXECUTIVE LEADERSHIP TEAM

Senda Biosciences | October 20, 2022

news image

Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the appointments of Lori Rudolph-Owen, Ph.D., as Chief Operating Officer, and Barbara Bispham, J.D., as SVP, General Counsel. "We're delighted to add Lori and Barbara to the Senda leadership team as we work to build a world-class organization. Each of these seasoned executives brings the skills and experience necessary to h...

Read More

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

news image

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More

RESEARCH

PRELLIS BIOLOGICS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB

Prellis Biologics, Inc. | January 14, 2022

news image

Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system based on human lymph node organoids. The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins. ...

Read More
news image

CELL AND GENE THERAPY

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More
news image

INDUSTRIAL IMPACT

SENDA BIOSCIENCES BOLSTERS EXECUTIVE LEADERSHIP TEAM

Senda Biosciences | October 20, 2022

Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the appointments of Lori Rudolph-Owen, Ph.D., as Chief Operating Officer, and Barbara Bispham, J.D., as SVP, General Counsel. "We're delighted to add Lori and Barbara to the Senda leadership team as we work to build a world-class organization. Each of these seasoned executives brings the skills and experience necessary to h...

Read More
news image

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More
news image

RESEARCH

PRELLIS BIOLOGICS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB

Prellis Biologics, Inc. | January 14, 2022

Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system based on human lymph node organoids. The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins. ...

Read More